TapewireFind a company

person · Reporting owner

MAETZOLD DEREK J

Disclosed activity across 1 company

Tapewire entity
17918
SEC CIK
0001239501

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CASTLE BIOSCIENCES INCCSTL · Entity 359Director · Pres. & Chief Exec. OfficerOctober 05, 2026October 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CASTLE BIOSCIENCES INC

Report date October 05, 2026 · Filed October 07, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect21,064 Ending reported balance After 2026-10-05 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-10-05 · Exercise / conversion · Acquired 8,165 · Balance 29,644

F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.

Row 2 · 2026-10-05 · Sale · Disposed 8,580 · Balance 21,064

F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.

F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Common StockSEC Table I · non-derivativeIndirectBy The Maetzold Descendants 2020 Trust8,038 Reported balance After 2026-10-05 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2026-10-05 · Sale · Disposed 3,198 · Balance 8,038

F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.

F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.

Common StockSEC Table I · non-derivativeIndirectBy Derek Maetzold 2020 Irrevocable Trust6,832 Reported balance After 2026-10-05 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 4 · 2026-10-05 · Sale · Disposed 2,718 · Balance 6,832

F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.

F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.

Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.39 · Expires 2028-05-09Direct0 Reported balance After 2026-10-05 transaction · row 13 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 13 · 2026-10-05 · Exercise / conversion · Disposed 8,165 · Balance 0

F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.

F13: The shares subject to the option are fully vested.

Common StockSEC Table I · non-derivativeIndirectBy The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk11,256 Reported balance Holding disclosure · report date 2026-10-05 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 11,256

F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.

Common StockSEC Table I · non-derivativeIndirectBy The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold11,256 Reported balance Holding disclosure · report date 2026-10-05 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 11,256

F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.

Common StockSEC Table I · non-derivativeIndirectBy The Maetzold 2018 Remainder Trust FBO John Derek Maetzold11,256 Reported balance Holding disclosure · report date 2026-10-05 · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · Balance 11,256

F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.

Common StockSEC Table I · non-derivativeIndirectBy The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold11,256 Reported balance Holding disclosure · report date 2026-10-05 · row 8 Holding and transaction disclosures are not merged.
1 source row

Row 8 · Balance 11,256

F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.

Common StockSEC Table I · non-derivativeIndirectBy DJM Grantor Retained Annuity Trust No. 611,963 Reported balance Holding disclosure · report date 2026-10-05 · row 9 Holding and transaction disclosures are not merged.
1 source row

Row 9 · Balance 11,963

F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.

Common StockSEC Table I · non-derivativeIndirectBy DJM Grantor Retained Annuity Trust No. 727,862 Reported balance Holding disclosure · report date 2026-10-05 · row 10 Holding and transaction disclosures are not merged.
1 source row

Row 10 · Balance 27,862

F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.

Common StockSEC Table I · non-derivativeIndirectBy DJM Grantor Retained Annuity Trust No. 840,935 Reported balance Holding disclosure · report date 2026-10-05 · row 11 Holding and transaction disclosures are not merged.
1 source row

Row 11 · Balance 40,935

F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary.

Common StockSEC Table I · non-derivativeIndirectDJM Grantor Retained Annuity Trust No. 923,216 Reported balance Holding disclosure · report date 2026-10-05 · row 12 Holding and transaction disclosures are not merged.
1 source row

Row 12 · Balance 23,216

F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary.

Filing footnotes · ownership attribution and instrument terms

F1: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.

F2: This transaction was executed in multiple trades at prices ranging from $35.310 to $35.965, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.

F4: Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries.

F5: Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary.

F6: Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.

F7: Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.

F8: Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary.

F9: Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold.

F10: Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.

F11: Held by DJM Grantor Retained Annuity Trust No. 8 of which the Reporting Person is the trustee and beneficiary.

F12: Held by DJM Grantor Retained Annuity Trust No. 9 of which the Reporting Person is the trustee and beneficiary.

F13: The shares subject to the option are fully vested.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 14, 2020 Filed Jul 16, 2020 20:34 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 100 $42.93 $4,293.00
Disclosure

SEC source: 0001447362-20-000148 · wf-form4_159493167583676.xml · nonDerivative · entry 6

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,594,348

F5 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020.

F8 · price: This transaction was executed in multiple trades at prices ranging from $42.93 to $42.94, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
July 14, 2020 Filed Jul 16, 2020 20:34 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 400 $42.16 $16,864.00
Disclosure

SEC source: 0001447362-20-000148 · wf-form4_159493167583676.xml · nonDerivative · entry 5

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,594,448

F5 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020.

F7 · price: This transaction was executed in multiple trades at prices ranging from $41.62 to $42.53, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
July 14, 2020 Filed Jul 16, 2020 20:34 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 500 $41.18 $20,590.00
Disclosure

SEC source: 0001447362-20-000148 · wf-form4_159493167583676.xml · nonDerivative · entry 4

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,594,848

F5 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2020.

F6 · price: This transaction was executed in multiple trades at prices ranging from $40.55 to $41.52, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
July 14, 2020 Filed Jul 16, 2020 20:34 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 1,839 $42.49 $78,139.11
Disclosure

SEC source: 0001447362-20-000148 · wf-form4_159493167583676.xml · nonDerivative · entry 3

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,595,348

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020.

F4 · price: This transaction was executed in multiple trades at prices ranging from $42.32 to $42.81, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
July 14, 2020 Filed Jul 16, 2020 20:34 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 7,036 $41.67 $293,190.12
Disclosure

SEC source: 0001447362-20-000148 · wf-form4_159493167583676.xml · nonDerivative · entry 2

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,597,187

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020.

F3 · price: This transaction was executed in multiple trades at prices ranging from $41.32 to $42.31, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
July 14, 2020 Filed Jul 16, 2020 20:34 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 13,125 $41.04 $538,650.00
Disclosure

SEC source: 0001447362-20-000148 · wf-form4_159493167583676.xml · nonDerivative · entry 1

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,604,223

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $40.32 to $41.31, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
June 09, 2020 Filed Jun 10, 2020 20:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 1,138 $38.39 $43,687.82
Disclosure

SEC source: 0001447362-20-000123 · wf-form4_159182007509330.xml · nonDerivative · entry 2

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,617,348

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020.

F3 · price: This transaction was executed in multiple trades at prices ranging from $38.09 to $38.67, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
June 09, 2020 Filed Jun 10, 2020 20:14 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 3,862 $37.62 $145,288.44
Disclosure

SEC source: 0001447362-20-000123 · wf-form4_159182007509330.xml · nonDerivative · entry 1

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,618,486

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $37.07 to $38.05, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 27, 2020 Filed May 28, 2020 20:09 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 444 $38.04 $16,889.76
Disclosure

SEC source: 0001447362-20-000088 · wf-form4_159069652619721.xml · nonDerivative · entry 3

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,622,348

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020.

F4 · price: This transaction was executed in multiple trades at prices ranging from $37.96 to $38.12, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 27, 2020 Filed May 28, 2020 20:09 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 2,556 $37.10 $94,827.60
Disclosure

SEC source: 0001447362-20-000088 · wf-form4_159069652619721.xml · nonDerivative · entry 2

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,622,792

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020.

F3 · price: This transaction was executed in multiple trades at prices ranging from $36.67 to $37.64, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 27, 2020 Filed May 28, 2020 20:09 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 2,000 $36.01 $72,020.00
Disclosure

SEC source: 0001447362-20-000088 · wf-form4_159069652619721.xml · nonDerivative · entry 1

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,625,348

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $35.52 to $36.38, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 22, 2020 Filed May 26, 2020 20:09 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 1,011 $37.53 $37,942.83
Disclosure

SEC source: 0001447362-20-000080 · wf-form4_159052373891673.xml · nonDerivative · entry 2

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,627,348

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020.

F3 · price: This transaction was executed in multiple trades at prices ranging from $37.31 to $37.98, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 22, 2020 Filed May 26, 2020 20:09 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 3,989 $36.83 $146,914.87
Disclosure

SEC source: 0001447362-20-000080 · wf-form4_159052373891673.xml · nonDerivative · entry 1

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,628,359

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $36.29 to $37.29, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 14, 2020 Filed May 18, 2020 20:03 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 10,000 $32.58 $325,800.00
Disclosure

SEC source: 0001447362-20-000066 · wf-form4_158983217168260.xml · nonDerivative · entry 1

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,632,348

F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 18, 2020.

F2 · price: This transaction was executed in multiple trades at prices ranging from $32.00 to $33.00, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 12, 2020 Filed May 14, 2020 20:04 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionStock option (right to buy) · Derivative 65,627 $0.00 Strike: $1.92 $0.00
Disclosure

SEC source: 0001447362-20-000061 · wf-form4_158948664897633.xml · derivative · entry 3

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,627 shares

Expires 2020-06-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to the option are fully vested.

Read SEC document
May 12, 2020 Filed May 14, 2020 20:04 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 65,627 $1.92 $126,003.84
Disclosure

SEC source: 0001447362-20-000061 · wf-form4_158948664897633.xml · nonDerivative · entry 1

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,642,348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 13, 2019 Filed Dec 17, 2019 21:13 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 GrantStock option (right to buy) · Derivative 170,000 $0.00 Strike: $29.50 $0.00
Disclosure

SEC source: 0001447362-19-000025 · wf-form4_157661717841630.xml · derivative · entry 1

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2029-12-12

F1 · derivative.exercise_date: 25% of the shares shall vest on December 13, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Read SEC document
July 29, 2019 Filed Jul 31, 2019 20:25 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 ConversionConvertible Promissory Note · Derivative Not disclosed Not disclosed Strike: $12.80 $100,000.00
Disclosure

SEC source: 0001209191-19-043859 · doc4.xml · derivative · entry 9

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,098 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The principal amount of the Convertible Promissory Note held by the Designated Reporting Person was $100,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.

F3 · reported_value: The principal amount of the Convertible Promissory Note held by the Designated Reporting Person was $100,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.

F3 · price: The principal amount of the Convertible Promissory Note held by the Designated Reporting Person was $100,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.

F3 · derivative.exercise_date: The principal amount of the Convertible Promissory Note held by the Designated Reporting Person was $100,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.

F3 · derivative.expiration_date: The principal amount of the Convertible Promissory Note held by the Designated Reporting Person was $100,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.

Read SEC document
July 29, 2019 Filed Jul 31, 2019 20:25 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 ConversionSeries F Preferred Stock · Derivative 1,859 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-043859 · doc4.xml · derivative · entry 8

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,524 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

Read SEC document
July 29, 2019 Filed Jul 31, 2019 20:25 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 ConversionSeries E-3 Preferred Stock · Derivative 486 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-043859 · doc4.xml · derivative · entry 7

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 398 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

Read SEC document
July 29, 2019 Filed Jul 31, 2019 20:25 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 ConversionSeries E-2 Preferred Stock · Derivative 546 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-043859 · doc4.xml · derivative · entry 6

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 447 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

Read SEC document
July 29, 2019 Filed Jul 31, 2019 20:25 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 ConversionSeries D Preferred Stock · Derivative 530 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-043859 · doc4.xml · derivative · entry 5

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 434 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

Read SEC document
July 29, 2019 Filed Jul 31, 2019 20:25 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 ConversionSeries A Preferred Stock · Derivative 102,954 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-043859 · doc4.xml · derivative · entry 4

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 84,455 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

Read SEC document
July 29, 2019 Filed Jul 31, 2019 20:25 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 ConversionCommon Stock 8,098 $12.80 $103,654.40
Disclosure

SEC source: 0001209191-19-043859 · doc4.xml · nonDerivative · entry 2

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,571,982

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The principal amount of the Convertible Promissory Note held by the Designated Reporting Person was $100,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.

Read SEC document
July 29, 2019 Filed Jul 31, 2019 20:25 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 ConversionCommon Stock 87,264 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-043859 · doc4.xml · nonDerivative · entry 1

MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,563,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The shares of Common Stock issued upon conversion of the Preferred Stock were calculated by first aggregating all series of Preferred Stock held by the Reporting Person, in accordance with the terms of the Company's then-effective Certificate of Incorporation.

F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.